Rockwell Medical, Inc. (RMTI)
USD 1.04
(1.96%)
USD 1.04
(1.96%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -6.67 Million USD | 60.25% |
| 2022 | -16.78 Million USD | 44.69% |
| 2021 | -30.33 Million USD | -6.74% |
| 2020 | -28.42 Million USD | 16.65% |
| 2019 | -34.09 Million USD | -5.11% |
| 2018 | -32.43 Million USD | -25.14% |
| 2017 | -25.92 Million USD | -28.28% |
| 2016 | -20.2 Million USD | -33.81% |
| 2015 | -15.1 Million USD | 13.99% |
| 2014 | -17.55 Million USD | 62.69% |
| 2013 | -47.05 Million USD | 13.27% |
| 2012 | -54.26 Million USD | -150.23% |
| 2011 | -21.68 Million USD | -655.85% |
| 2010 | -2.86 Million USD | 47.66% |
| 2009 | -5.48 Million USD | 32.2% |
| 2008 | -8.08 Million USD | -124.07% |
| 2007 | -3.6 Million USD | 22.2% |
| 2006 | -4.63 Million USD | -3474.56% |
| 2005 | 137.43 Thousand USD | -66.41% |
| 2004 | 409.18 Thousand USD | 117.75% |
| 2003 | 187.9 Thousand USD | 121.79% |
| 2002 | -862.18 Thousand USD | 40.14% |
| 2001 | -1.44 Million USD | -37.87% |
| 2000 | -1.04 Million USD | 5.02% |
| 1999 | -1.1 Million USD | 45.0% |
| 1998 | -2 Million USD | -5.26% |
| 1997 | -1.9 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -1.32 Million USD | -142.05% |
| 2024 Q2 | 515 Thousand USD | 138.9% |
| 2023 FY | -6.67 Million USD | 60.25% |
| 2023 Q4 | -547 Thousand USD | 68.51% |
| 2023 Q1 | -1.42 Million USD | 27.42% |
| 2023 Q2 | -2.95 Million USD | -107.36% |
| 2023 Q3 | -1.73 Million USD | 41.3% |
| 2022 Q1 | -6.62 Million USD | 20.73% |
| 2022 Q2 | -4.48 Million USD | 32.36% |
| 2022 Q3 | -3.7 Million USD | 17.27% |
| 2022 Q4 | -1.96 Million USD | 46.98% |
| 2022 FY | -16.78 Million USD | 44.69% |
| 2021 Q1 | -7.18 Million USD | 11.03% |
| 2021 Q3 | -6.97 Million USD | 10.88% |
| 2021 Q4 | -8.35 Million USD | -19.89% |
| 2021 Q2 | -7.82 Million USD | -8.93% |
| 2021 FY | -30.33 Million USD | -6.74% |
| 2020 Q2 | -5.6 Million USD | 30.43% |
| 2020 FY | -28.42 Million USD | 16.65% |
| 2020 Q4 | -8.07 Million USD | -20.66% |
| 2020 Q3 | -6.69 Million USD | -19.39% |
| 2020 Q1 | -8.05 Million USD | -8.81% |
| 2019 Q2 | -10.37 Million USD | -17.72% |
| 2019 Q1 | -8.8 Million USD | 6.53% |
| 2019 FY | -34.09 Million USD | -5.11% |
| 2019 Q4 | -7.4 Million USD | 6.79% |
| 2019 Q3 | -7.94 Million USD | 23.42% |
| 2018 Q4 | -9.42 Million USD | -88.55% |
| 2018 Q3 | -4.99 Million USD | 59.35% |
| 2018 FY | -32.43 Million USD | -25.14% |
| 2018 Q1 | -6.69 Million USD | 27.35% |
| 2018 Q2 | -12.29 Million USD | -83.57% |
| 2017 FY | -25.92 Million USD | -28.28% |
| 2017 Q4 | -9.22 Million USD | -83.5% |
| 2017 Q3 | -5.02 Million USD | 25.2% |
| 2017 Q2 | -6.71 Million USD | -35.5% |
| 2017 Q1 | -4.95 Million USD | 5.78% |
| 2016 Q1 | -4.6 Million USD | 24.03% |
| 2016 FY | -20.2 Million USD | -33.81% |
| 2016 Q4 | -5.26 Million USD | -10.73% |
| 2016 Q2 | -5.58 Million USD | -21.32% |
| 2016 Q3 | -4.75 Million USD | 14.96% |
| 2015 Q2 | -2.65 Million USD | 30.37% |
| 2015 Q4 | -6.06 Million USD | -135.81% |
| 2015 FY | -15.1 Million USD | 13.99% |
| 2015 Q1 | -3.81 Million USD | 24.06% |
| 2015 Q3 | -2.57 Million USD | 3.15% |
| 2014 Q2 | -2.38 Million USD | 66.09% |
| 2014 Q4 | -5.02 Million USD | -60.37% |
| 2014 Q3 | -3.13 Million USD | -31.44% |
| 2014 Q1 | -7.02 Million USD | 6.69% |
| 2014 FY | -17.55 Million USD | 62.69% |
| 2013 Q1 | -15.39 Million USD | -12.47% |
| 2013 FY | -47.05 Million USD | 13.27% |
| 2013 Q4 | -7.52 Million USD | 39.11% |
| 2013 Q3 | -12.36 Million USD | -5.0% |
| 2013 Q2 | -11.77 Million USD | 23.49% |
| 2012 Q2 | -11.98 Million USD | -12.21% |
| 2012 Q4 | -13.68 Million USD | 23.63% |
| 2012 FY | -54.26 Million USD | -150.23% |
| 2012 Q1 | -10.67 Million USD | -19.23% |
| 2012 Q3 | -17.91 Million USD | -49.54% |
| 2011 FY | -21.68 Million USD | -655.85% |
| 2011 Q4 | -8.95 Million USD | -75.04% |
| 2011 Q3 | -5.11 Million USD | -10.85% |
| 2011 Q2 | -4.61 Million USD | -53.97% |
| 2011 Q1 | -2.99 Million USD | -64.7% |
| 2010 Q3 | -759.15 Thousand USD | -796.11% |
| 2010 Q1 | -398.78 Thousand USD | 27.55% |
| 2010 Q2 | 109.05 Thousand USD | 127.35% |
| 2010 FY | -2.86 Million USD | 47.66% |
| 2010 Q4 | -1.82 Million USD | -139.75% |
| 2009 Q1 | -1.7 Million USD | 44.45% |
| 2009 Q4 | -550.41 Thousand USD | 63.73% |
| 2009 Q2 | -1.7 Million USD | -0.07% |
| 2009 FY | -5.48 Million USD | 32.2% |
| 2009 Q3 | -1.51 Million USD | 11.12% |
| 2008 FY | -8.08 Million USD | -124.07% |
| 2008 Q1 | -1.35 Million USD | -17.41% |
| 2008 Q4 | -3.07 Million USD | -21.46% |
| 2008 Q2 | -1.12 Million USD | 16.64% |
| 2008 Q3 | -2.52 Million USD | -123.85% |
| 2007 FY | -3.6 Million USD | 22.2% |
| 2007 Q3 | -380.93 Thousand USD | 13.87% |
| 2007 Q2 | -442.29 Thousand USD | 72.89% |
| 2007 Q1 | -1.63 Million USD | -37.62% |
| 2007 Q4 | -1.15 Million USD | -202.99% |
| 2006 FY | -4.63 Million USD | -3474.56% |
| 2006 Q3 | -1.62 Million USD | -5.28% |
| 2006 Q1 | -291.27 Thousand USD | -40.39% |
| 2006 Q4 | -1.18 Million USD | 26.87% |
| 2006 Q2 | -1.53 Million USD | -428.68% |
| 2005 Q2 | 121.97 Thousand USD | 460.64% |
| 2005 Q3 | 201.16 Thousand USD | 64.92% |
| 2005 Q4 | -207.46 Thousand USD | -203.13% |
| 2005 FY | 137.43 Thousand USD | -66.41% |
| 2005 Q1 | 21.75 Thousand USD | -69.35% |
| 2004 Q2 | 99.26 Thousand USD | -20.3% |
| 2004 Q4 | 70.98 Thousand USD | -37.95% |
| 2004 FY | 409.18 Thousand USD | 117.75% |
| 2004 Q1 | 124.54 Thousand USD | -14.47% |
| 2004 Q3 | 114.39 Thousand USD | 15.24% |
| 2003 Q4 | 145.61 Thousand USD | 15.64% |
| 2003 Q2 | -36.19 Thousand USD | 23.7% |
| 2003 Q1 | -47.43 Thousand USD | 4.4% |
| 2003 FY | 187.9 Thousand USD | 121.79% |
| 2003 Q3 | 125.92 Thousand USD | 447.92% |
| 2002 Q3 | -142.09 Thousand USD | 59.89% |
| 2002 Q4 | -49.61 Thousand USD | 65.08% |
| 2002 Q1 | -316.21 Thousand USD | 18.52% |
| 2002 FY | -862.18 Thousand USD | 40.14% |
| 2002 Q2 | -354.24 Thousand USD | -12.03% |
| 2001 Q1 | -278.76 Thousand USD | -120.92% |
| 2001 FY | -1.44 Million USD | -37.87% |
| 2001 Q4 | -388.1 Thousand USD | 11.02% |
| 2001 Q3 | -436.16 Thousand USD | -29.3% |
| 2001 Q2 | -337.32 Thousand USD | -21.0% |
| 2000 Q3 | -305.21 Thousand USD | 15.76% |
| 2000 Q2 | -362.33 Thousand USD | -44.36% |
| 2000 Q1 | -250.99 Thousand USD | -151.0% |
| 2000 Q4 | -126.18 Thousand USD | 58.66% |
| 2000 FY | -1.04 Million USD | 5.02% |
| 1999 Q1 | -300 Thousand USD | 0.0% |
| 1999 Q4 | -100 Thousand USD | 66.67% |
| 1999 Q3 | -300 Thousand USD | 25.0% |
| 1999 FY | -1.1 Million USD | 45.0% |
| 1999 Q2 | -400 Thousand USD | -33.33% |
| 1998 Q4 | -300 Thousand USD | 40.0% |
| 1998 FY | -2 Million USD | -5.26% |
| 1998 Q1 | -500 Thousand USD | -25.0% |
| 1998 Q2 | -400 Thousand USD | 20.0% |
| 1998 Q3 | -500 Thousand USD | -25.0% |
| 1997 Q4 | -400 Thousand USD | 0.0% |
| 1997 FY | -1.9 Million USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alvotech | -354.86 Million USD | 98.12% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 103.995% |
| Journey Medical Corporation | -2.07 Million USD | -221.756% |
| Dynavax Technologies Corporation | -37.02 Million USD | 81.987% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 95.815% |
| PainReform Ltd. | -9.58 Million USD | 30.405% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -39.385% |
| SCYNEXIS, Inc. | 72.66 Million USD | 109.179% |
| Silver Spike Investment Corp. | 7.34 Million USD | 190.871% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -39.385% |
| Bright Green Corporation | -8.89 Million USD | 24.984% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 95.712% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 55.834% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 114.2% |
| Alpha Teknova, Inc. | -35.56 Million USD | 81.245% |
| Embecta Corp. | 221.5 Million USD | 103.011% |
| Safety Shot Inc | -12.18 Million USD | 45.257% |
| Procaps Group, S.A. | 38.97 Million USD | 117.114% |
| Cosmos Health Inc. | -21.83 Million USD | 69.447% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -165.186% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 107.608% |
| Theratechnologies Inc. | -10.62 Million USD | 37.235% |
| Harrow Health, Inc. | 580 Thousand USD | 1250.0% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -41.885% |
| Biofrontera Inc. | -22.67 Million USD | 70.587% |
| DURECT Corporation | -36.88 Million USD | 81.916% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -26.589% |
| Cronos Group Inc. | -81.37 Million USD | 91.803% |
| OptiNose, Inc. | -22.74 Million USD | 70.679% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 103.191% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 82.964% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 152.802% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 153.253% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | -53.817% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -7.393% |
| Radius Health, Inc. | -3.92 Million USD | -69.936% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -89.125% |
| ProPhase Labs, Inc. | -21.61 Million USD | 69.139% |
| Phibro Animal Health Corporation | 53.31 Million USD | 112.511% |
| Procaps Group S.A. | 52.32 Million USD | 112.747% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 21.741% |
| Viatris Inc. | 766.2 Million USD | 100.871% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -26.951% |
| SIGA Technologies, Inc. | 83.62 Million USD | 107.976% |
| Tilray Brands, Inc. | -174.74 Million USD | 96.183% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 171.482% |
| Shineco, Inc. | -17.06 Million USD | 60.916% |
| PetIQ, Inc. | 60.01 Million USD | 111.114% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -40.815% |
| Incannex Healthcare Limited | -30.04 Million USD | 77.797% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 102.658% |
| Alimera Sciences, Inc. | -1.47 Million USD | -353.433% |
| Assertio Holdings, Inc. | -243.53 Million USD | 97.261% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -13.197% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 51.018% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | 57.227% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 66.733% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 95.161% |
| Hempacco Co., Inc. | -8.81 Million USD | 24.31% |
| Talphera, Inc. | -16.88 Million USD | 60.507% |
| Alvotech | -354.86 Million USD | 98.12% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 112.478% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 101.829% |
| Currenc Group, Inc. | -6.64 Million USD | -0.364% |
| Kamada Ltd. | 10.06 Million USD | 166.276% |
| Indivior PLC | -4 Million USD | -66.75% |
| Evoke Pharma, Inc. | -7.43 Million USD | 10.24% |
| Flora Growth Corp. | -50.35 Million USD | 86.754% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 66.733% |
| Evolus, Inc. | -49.23 Million USD | 86.452% |
| HUTCHMED (China) Limited | 18.37 Million USD | 136.299% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 103.386% |
| Akanda Corp. | -10.05 Million USD | 33.641% |